MYCN and neoplasm: As previously reported by our group, a higher incidence of MYCN gene amplification was noted in the patients of MED when compared with the NAD group (44.11% v 20.45%, respectively).3 Among the 24 MYCN-amplified cases in our cohort (24 of 78), the percentage of neoplastic cells showing evidence of MYCN gene amplification in a given tumor ranged from 18.5% to 100%, with an average of 87.89%.